September 1, 2022 — IBA S.A., a leader in particle accelerator technology and a leader in dosimetry quality assurance solutions, and ScandiDos A.B. (SDOS.ST), a technology leader in advanced Radiation Therapy Quality Assurance, announced that they have formed a strategic alliance for radiation therapydosimetry solutions. The collaboration will enable the two businesses to work together on product development, marketing and product distribution in selected markets, for patient quality assurance for radiotherapy. Specifics of the collaboration will be developed jointly by the parties in the coming months.
IBA Dosimetry and ScandiDos have secured this collaboration as part of their shared vision for a complete radiotherapy quality assurance solution. By combining the portfolios of both companies, IBA Dosimetry and ScandiDos can accomplish this vision, offering an increasingly extensive suite of products that provide a consistent solution for all aspects of radiotherapy quality assurance.
Under the terms of the agreement, IBA will purchase the full share issue (4,150,000 shares) made by ScandiDos on 30 August at a price of SEK 3.00, corresponding to an 8% premium on the average of the company’s last 12 month’s trading on the Stockholm stock exchange. Following the transaction IBA will hold 9.1% of ScandiDos A.B.’s share capital.
Jean-Marc Bothy, President of IBA Dosimetry, said: “This is an important milestone in our ongoing industry consolidation strategy. We are proud ScandiDos have chosen us as their partner for their expansion. For years, we have been impressed with the quality of the ScandiDos’ product portfolio in patient quality assurance and believe it is complementary to our rapidly expanding equipment and software offering. The combination of both companies’ product offerings will provide a unique level of quality, simplicity, and versatility to the medical physics community allowing them to deliver the full benefit of radiation therapy, with enhanced safety profiles to cancer patients everywhere.”
Gustaf Piehl, CEO of ScandiDos AB, added “Sharing a similar, long-term view of the quality assurance market for radiation therapy has been fundamental to building this alliance. By collaborating with IBA, a leading industry partner, ScandiDos will reach more customers on a global scale and contribute to making radiation treatment even safer than it is today. This strategic collaboration will also allow ScandiDos to maintain its independence to further develop the business while leveraging on IBA’s strong organizational capabilities.”
For more information: www.iba-worldwide.com
June 01, 2023 
